Liver Cancer Molecular Diagnostics Market Size, Share | Industry Report 2025

The global liver cancer molecular diagnostics market was valued at $115.3 Million in 2017 and is forecast to grow at a modest 13.7 % CAGR between 2018 and 2025, culminating in 2025 global sales of $355.2 Million.

Individualized and targeted treatments are reshaping oncology. Key to personalized medicine lies in molecular pathology. Use of high throughput sequencing technologies and identification of therapeutic targets has led to the development of many molecular diagnostic tests, which are far more superior to the conventional pathology tests. Despite recent development in novel targets and potential markers, the implementation of tests to identify in clinical and pathology practice is hard to achieve.

Global oncology molecular diagnostic market is expected to grow at a faster rate than expected due to rising demand from physicians, failure rate of conventional diagnosis, better and early detection, reducing cost of molecular diagnostic, improvement reimbursement coverage, technological, rising prevalence of chronic diseases and rapid increase in the geriatric population across the globe. Moreover, high unmet needs across the developing and emerging nations is also expected to boost the molecular diagnostics over the next few years.

Liver cancer is more prevalent in countries in sub-Saharan Africa and Southeast Asia than in the US. In many of these countries it is the most common type of cancer. More than 700,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year. There are various types of primary liver cancer occur in adults. Some of the most common liver cancers include Hepatocellular carcinoma, Cholangiocarcinoma (bile duct cancer), and Angiosarcoma. These are named after the cells from which they developed. Among these, 80% of adult primary liver cancers are hepatocellular carcinomas, 10% to 20% of adult primary liver cancers are cholangiocarcinomas and only 1% of adult primary liver cancers are angiosarcomas. The outlook for liver cancer is poor, as it is often diagnosed at a late stage, at which point it has already spread to other organs or other parts of the liver. The survival rate reduces as the staging gets closer to Stage IV. People diagnosed at an early stage have a 5-year survival rate of 31%.
.

Aging factors significantly contribute to the onset of several oncological conditions. For instance, the average age for stomach cancer diagnosis is 69 and about every 6 in 10 patients diagnosed are aged above 65. The American Cancer Society estimates that nearly 28,000 stomach cancer cases will be diagnosed in 2017, with 17,750 cases in men and 10,250 cases in women. In the UK, as per 2014 Cancer Research estimates, each year nearly 6,682 new cases are detected, and the average survival rate is 15%.

North America accounted for over 46% revenue share in 2016. The key reasons attributed for the high share include the high prevalence of stomach and GI cancers, strong reimbursement framework, highly skilled medical professionals, technological advancements and government support for R&D and innovation in medical devices sector. Moreover, the presence of high-end hospital and POC and high emphasis on preventive screening is expected to boost the usage rates over the forecast period.

Asia Pacific is expected to register the maximum CAGR of 7.5% through 2017 to 2025. The rapid increase in a number of cancer cases, growing healthcare expenditure and skill training, and improvement in reimbursement scenario are expected to favor the high market growth in the region.

Click the link below to view the report description:
www.ameriresearch.com/product/liver-cancer-molecular-diagnostics-market/

Key findings from the study: -
• Global oncology molecular diagnostic market is expected to grow at a faster rate than expected due to rising demand from physicians, failure rate of conventional diagnosis, better and early detection, reducing cost of molecular diagnostic, improvement reimbursement coverage, technological, rising prevalence of chronic diseases and rapid increase in the geriatric population across the globe.
• Reagents and kits are a large component of the overall market for Oncology Molecular Diagnostic. There are several options in the market for a wide range of usages from Thermo Fisher to Qiagen to Luminous Bioscience.
• Major players in the market include Cepheid, Beckton Dickinson, Gen Probe (Hologic), Qiagen, Roche Diagnostics, Bayer Healthcare, Dako, Abbott Laboratories, Danaher Corporation, Siemens, Sysmex Corporation, Grifols, and Biomérieux Sa.

Ameri Research has segmented the Liver Cancer Molecular Diagnostics Market by Products, Test Location, Technology and Regional Outlook.

Market Segmentation:

Liver Cancer Molecular Diagnostics Market by Products (Revenue, USD Million, 2014 – 2025)
• Instruments
• Reagents & Kits
• Software & Services

Liver Cancer Molecular Diagnostics Market by Test Location (Revenue, USD Million, 2014- 2025)
• Clinics/Lab
• Point of Care

Liver Cancer Molecular Diagnostics Market by Technology (Revenue, USD Million, 2014- 2025)
• PCR
• In Situ Hybridization
• Chips and microarrays
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Mass spectrometry
• Sequencing
• Transcription Mediated Amplification

Liver Cancer Molecular Diagnostics Systems Regional Outlook (Revenue, USD Million, 2014- 2025)
• North America
o U.S.
o Canada

• Europe
o UK
o Germany
o France
o Italy
o Spain

• Asia Pacific
o Japan
o China
o India
o Australia

• Latin America
o Brazil
o Mexico
o Columbia

• Middle East and Africa
o South Africa
o Saudi Arabia

Browse Full Report @ www.ameriresearch.com/product/liver-cancer-molecular-diagnostics-market/

About Us:

Ameri Research Inc. (www.ameriresearch.com) is a U.S. based market research and consulting company, registered in the State of Florida and headquartered in Tampa Bay Area. At Ameri Research we are passionately curious about people, markets, brands and society. Our ability to gauge market movements, deep expertise in data science, strong domain expertise and years of collective global experiences helps us to bring unmatched quality in deliverables to our clients. With carefully planned systems and processes in place, we cater to the requirements of our clients in a timely and cost-efficient manner, bringing increased predictability to their business. Each year we are publishing more than 100 syndicated reports in healthcare, chemicals, materials, food & beverages, defense & aerospace, media & entertainment, sports & fitness, and energy. We offer our clients a unique depth of knowledge and expertise around-

Market Mapping
Opportunity Assessment
Positioning
Pricing Analysis
Market Entry Strategy
Competitive Intelligence
Program Evaluation
Performance Reporting
Data Analytics
Developing a culture of collaboration and curiosity, we attract the highest caliber of likeminded people having ability to influence and shape the future.

Follow us on LinkedIn for our latest upcoming reports www.linkedin.com/company/ameri-research-inc./
Follow us on Facebook for our latest upcoming reports www.facebook.com/AmeriResearchInc/
Follow us on Twitter for our latest upcoming reports www.twitter.com/AmeriResearch

Contact Us:

Ameri Research Inc.
6816 Muncaster Ct,
Tampa, FL 33625
United States.
Tel: 1-813-666-0858
Email: Inquiry@ameriresearch.com
Web: www.ameriresearch.com

This release was published on openPR.